Abstract
To date, no data of patients with TMS who underwent PET imaging with [18F]fluorodopa are available. We here present the case of a 71-year-old woman with relapse and remission MS originally diagnosed 15 years earlier. Before 2 years, a bilateral breast cancer was also diagnosed and treated with surgery and chemotherapy. The present case highlights the role of [18F]fluorodopa for the differential diagnosis between TMS and metastatic lesions from breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Readings
Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378:169–80.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73.
Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: a comprehensive review. Mult Scler Relat Disord. 2017;14:72–9.
Bauckneht M, Capitanio S, Raffa S, Roccatagliata L, Pardini M, Lapucci C, et al. Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers. EJNMMI Radiopharm Chem. 2019;4:6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Morbelli, S., Raffa, S. (2022). Case 33: Tumefactive Multiple Sclerosis Lesions (TMS). In: Varrone, A., Morbelli, S., Garibotto, V. (eds) Clinical Nuclear Medicine in Neurology. Springer, Cham. https://doi.org/10.1007/978-3-030-83598-9_33
Download citation
DOI: https://doi.org/10.1007/978-3-030-83598-9_33
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-83597-2
Online ISBN: 978-3-030-83598-9
eBook Packages: MedicineMedicine (R0)